Aurinia ( AUPH ) Upgraded to Buy: Here's What You Should Know
Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aurinia ( AUPH ) Q2 Revenue Jumps 22%
Aurinia Pharmaceuticals ( NASDAQ:AUPH ) , a biopharmaceutical company focused on therapies for autoimmune diseases, released its second-quarter 2025 earnings on July 31, 2025. The headline news: revenue ( GAAP ) came in at $70.0 million, which exceeded analyst expectations of $63.8 million by ...
Aurinia Pharmaceuticals ( AUPH ) Q2 Earnings Miss Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of -5.88% and +10.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options
Investors need to pay close attention to AUPH stock based on the movements in the options market lately.
Aurinia ( AUPH ) Surges 7.5%: Is This an Indication of Further Gains?
Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals ( AUPH ) Stock?
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert - Advance Auto Parts ( NYSE:AAP ) , Autodesk ( NASDAQ:ADSK )
U.S. stock futures were fluctuating on Friday after a mixed close on Thursday. Futures of major benchmark indices were mixed in premarket.
Company News for May 13, 2025
Companies in The News Are: ...
Aurinia Profits As Q1 Sales Jump 24%, Sticks To Guidance - Aurinia Pharmaceuticals ( NASDAQ:AUPH )
Aurinia reported $0.16 EPS in Q1 vs. $ ( 0.07 ) last year, beating estimates of $0.10. LUPKYNIS sales rose 25% year over year to $60 million in Q1. Get our list of 10 overlooked stocks-including one paying a 9% dividend-before Wall Street catches on. Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals ( AUPH ) Surpasses Q1 Earnings and Revenue Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of 100% and 2.63%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics
Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics are part of the Zacks Industry Outlook article.
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.
Strength Seen in Xeris Biopharma ( XERS ) : Can Its 5.6% Jump Turn into More Strength?
Xeris Biopharma (XERS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals ( AUPH ) Stock?
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations - Aurinia Pharmaceuticals ( NASDAQ:AUPH )
Aurinia posted Q4 earnings of 1 cent per share, beating the expected loss of 2 cents; Sales spiked 33% to $59.9M, in line with estimates. LUPKYNIS net sales reached $57.6M, up 36% YoY, while 2024 total net product sales hit $216.2M, meeting management's guidance.
Aurinia Pharmaceuticals ( AUPH ) Beats Q4 Earnings and Revenue Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of 200% and 0.25%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Corcept ( CORT ) Soars 13.6%: Is Further Upside Left in the Stock?
Corcept (CORT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Aurinia ( AUPH ) Upgraded to Buy: Here's Why
Aurinia (AUPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Implied Volatility Surging for Aurinia Pharmaceuticals ( AUPH ) Stock Options
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
Aurinia Pharmaceuticals ( AUPH ) Q3 Earnings and Revenues Beat Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of 400% and 14.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors - Context Therapeutics ( NASDAQ:CNTX )
PHILADELPHIA, Sept. 04, 2024 ( GLOBE NEWSWIRE ) -- Context Therapeutics Inc. ( "Context" or the "Company" ) CNTX, a biopharmaceutical company advancing medicines for solid tumors, today announced the appointments of Karen Smith, MD, PhD, MBA, LLM and Luke Walker, MD, to its Board of Directors.
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategy The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical ...
Do Options Traders Know Something About Aurinia ( AUPH ) Stock We Don't?
Investors need to pay close attention to Aurinia (AUPH) stock based on the movements in the options market lately.
Aurinia Pharmaceuticals ( AUPH ) Q2 Earnings and Revenues Beat Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of 100% and 4.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Aurinia ( AUPH ) Soars 6.6%: Is Further Upside Left in the Stock?
Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Strength Seen in Aurinia ( AUPH ) : Can Its 5.6% Jump Turn into More Strength?
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Rheumatologists' Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
EXTON, PA, June 13, 2024 ( GLOBE NEWSWIRE ) -- Since 2021, the treatment options for systemic lupus erythematosus ( SLE ) and lupus nephritis ( LN ) have expanded with the approval of AstraZeneca's Saphnelo ( anifrolumab ) for SLE, a label extension for GSK's Benlysta ( belimumab ) for LN in ...
ILJIN SNT Co., Ltd. Announces Its Intention to Vote Against Aurinia Pharmaceuticals's Revised Equity Incentive Plan Proposal
SEOUL, South Korea, June 7, 2024 /CNW/ -- ILJIN SNT Co., Ltd. ( "ILJIN" ) is a long-standing investor of Aurinia Pharmaceuticals Inc. ( "Aurinia" or the "Company" ) , and, together with its affiliates, currently holds more than 5% of Aurinia's common stock.
ILJIN SNT Co., Ltd. Announces Its Intention to Vote Against Aurinia Pharmaceuticals's Revised Equity Incentive Plan Proposal
SEOUL, South Korea, June 7, 2024 /PRNewswire/ -- ILJIN SNT Co., Ltd. ( "ILJIN" ) is a long-standing investor of Aurinia Pharmaceuticals Inc. ( "Aurinia" or the "Company" ) , and, together with its affiliates, currently holds more than 5% of Aurinia's common stock.
news
aurinia pharmaceuticals inc. Press Releases | Cision Canada ...
ILJIN SNT Co., Ltd. Calls for Board Restructure at Aurinia Pharmaceuticals
SEOUL, South Korea, May 20, 2024 /CNW/ -- ILJIN SNT Co., Ltd. and its affiliates ( collectively, "ILJIN" ) is a long-term holder of more than 5% of Aurinia Pharmaceuticals Inc. ( "Aurinia" or the "Company" ) and has been supportive of the Company's mission since 2010 when we invested in the ...
ILJIN SNT Co., Ltd. Calls for Board Restructure at Aurinia Pharmaceuticals
SEOUL, South Korea, May 20, 2024 /PRNewswire/ -- ILJIN SNT Co., Ltd. and its affiliates ( collectively, "ILJIN" ) is a long-term holder of more than 5% of Aurinia Pharmaceuticals Inc. ( "Aurinia" or the "Company" ) and has been supportive of the Company's mission since 2010 when we invested in ...
How Much Upside is Left in Aurinia ( AUPH ) ? Wall Street Analysts Think 96.51%
The average of price targets set by Wall Street analysts indicates a potential upside of 96.5% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Aurinia Pharmaceuticals ( NASDAQ:AUPH ) Upgraded by StockNews.com to Buy
StockNews.com upgraded shares of Aurinia Pharmaceuticals ( NASDAQ:AUPH - Free Report ) ( TSE:AUP ) from a hold rating to a buy rating in a research note released on Friday morning. Several other analysts also recently issued reports on the stock.
Aurinia Pharmaceuticals ( AUPH ) Reports Q1 Loss, Tops Revenue Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of 82.35% and 8.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors - Mirum Pharmaceuticals ( NASDAQ:MIRM ) , Century Therapeutics ( NASDAQ:IPSC )
SAN MATEO, Calif., March 25, 2024 ( GLOBE NEWSWIRE ) -- Sagimet Biosciences Inc. ( ( Sagimet, NASDAQ:SGMT ) , a clinical-stage biopharmaceutical company developing novel fatty acid synthase ( FASN ) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the ...
Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair
WINNIPEG, Manitoba, Feb. 22, 2024 ( GLOBE NEWSWIRE ) -- Kane Biotech Inc. ( TSX-V:KNE OTCQB:KNBIF ) ( the "Company" or "Kane Biotech" or "Kane" ) announces that at the special meeting of the shareholders of the Company held on February 20, 2024, Dr. Robert Huizinga was elected as a director of ...
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday - Analog Devices ( NASDAQ:ADI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler raised the price target for Wix.com Ltd. WIX from $146 to $165.
Why Is Aurinia Pharmaceuticals Stock Trading Lower Today? - Aurinia Pharmaceuticals ( NASDAQ:AUPH )
Aurinia Pharmaceuticals Inc AUPH reported a fourth-quarter 2023 EPS loss of $ ( 0.19 ) , missing the consensus of $ ( 0.16 ) and a bit higher than $ ( 0.18 ) a year ago. The company reported sales of $45.1 million, beating the consensus of $44.33 million.
Aurinia Pharmaceuticals ( AUPH ) Reports Q4 Loss, Tops Revenue Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of -5.56% and 3.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Esperion Therapeutics ( ESPR ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurinia Pharmaceuticals ( AUPH ) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Aurinia (AUPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kane Biotech Announces Special Meeting of Shareholders
WINNIPEG, Manitoba, Jan. 18, 2024 ( GLOBE NEWSWIRE ) -- Kane Biotech Inc. ( TSX-V:KNE OTCQB:KNBIF ) ( the "Company", "Kane" or "Kane Biotech" ) announces today that on February 20, 2024, the Company will hold a special meeting of its shareholders ( the "Meeting" ) to consider the election of Dr. ...
What's Going On With Aurinia Pharmaceuticals Stock? - Aurinia Pharmaceuticals ( NASDAQ:AUPH )
Aurinia Pharmaceuticals, Inc. AUPH shares are trending on social media Friday. The company provided its preliminary, unaudited fourth-quarter and fiscal year 2023 financial results.
Are Medical Stocks Lagging Aurinia Pharmaceuticals ( AUPH ) This Year?
Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Is it a Good Idea to Buy Journey Medical ( DERM ) Stock Now?
Here, we discuss some reasons why investing in Journey Medical (DERM) stock now may turn out to be a prudent move.
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical
Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article.
5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year
Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.
Are Medical Stocks Lagging ADMA Biologics ( ADMA ) This Year?
Here is how Adma Biologics (ADMA) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.
Can Aurinia ( AUPH ) Climb 46.13% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 46.1% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
